Interleukin-2 (IL-2), which is a growth factor for T lymphocytes, can also sometimes be inhibitory. Thus, the proliferation of CD8+ T cells in vivo is increased after the injection of a monoclonal antibody that is specific for IL-2 (IL-2 mAb), perhaps reflecting the removal of IL-2-dependent CD4+ T regulatory cells (T regs). Instead, we show here that IL-2 mAb augments the proliferation of CD8+ cells in mice simply by increasing the biological activity of preexisting IL-2 through the formation of immune complexes. When coupled with recombinant IL-2, some IL-2/IL-2 mAb complexes cause massive (>100-fold) expansion of CD8+ cells in vivo, whereas others selectively stimulate CD4+ T regs. Thus, different cytokine-antibody complexes can be used to selectively boost or inhibit the immune response.
IL-15 is normally not secreted in soluble form (8-10) but is held on the cell surface bound to a unique receptor, IL-15R␣, especially on dendritic cells (11-16). Cell-bound IL-15 then is presented in trans to T cells and NK cells and is recognized by the ␥ c receptor on these cells; such recognition maintains cell survival and intermittent proliferation.IL-15R␣ plays a mandatory role in presenting endogenous IL-15. Thus, like IL-15 -/-mice (1), IL-15R␣ -/-mice lack CD122 hi CD8 ϩ cells and NK cells (17), presumably because the IL-15 synthesized in IL-15R␣ -/-mice fails to leave the cytoplasm. Nevertheless, ␥ c ϩ cells can proliferate in response to a soluble recombinant form of IL-15 in the absence of IL-15R␣ (18). Moreover, under certain conditions, IL-15R␣ can be inhibitory. Thus, injecting mice with a soluble (s) recombinant form of IL-15R␣ is reported to suppress NK cell proliferation (10) and certain T dependent immune responses in vivo (19)(20)(21)(22), and adding sIL-15R␣ in vitro can block the response of cell lines to . Despite these findings, there are other reports that sIL-15R␣ (26), and also a soluble sushi domain of IL-15R␣ (27), can enhance IL-15 responses of human cell lines.In this paper, we investigated whether sIL-15R␣ can alter the response of normal mouse T cells to IL-15. As discussed below, IL-15 responses of CD8 ϩ T cells and NK cells are improved considerably by association with sIL-15R␣, both in vitro and in vivo. Results Stimulation by IL-15͞IL-15R␣ Complexes in Vitro.To examine whether the stimulatory function of soluble IL-15 is altered by binding to sIL-15R␣, purified MP CD44 hi CD122 hi CD8 ϩ cells were cultured in vitro with mouse IL-15 Ϯ mouse sIL-15R␣ covalently linked to the Fc portion of human IgG1 (sIL-15R␣-Fc). For IL-15 alone, half-maximal responses required Ϸ30 ng͞ml and responses were negligible with Ͻ10 ng͞ml (Fig. 1A and B). Here, the notable finding was that supplementing a low concentration of IL-15, e.g., 5 ng͞ml, with sIL-15R␣-Fc led to strong proliferative responses of MP CD8 ϩ cells as measured either by carboxyf luorescein diacetate succinimidyl ester (CFSE) dilution (Fig. 1 A) or by [ 3 H]thymidine incorporation (Fig. 1B). No proliferation occurred with sIL-15R␣-Fc alone (Fig. 1B), and the addition of sIL-15R␣-Fc failed to alter the response of MP CD8 ϩ cells to a different cytokine, IL-2 (data not shown). With IL-15, sIL-15R␣-Fc did not appear to act by enhancing the half-life of IL-15 in vitro (Fig. 6, which is published as supporting information on the PNAS web site).With a limiting concentration of cytokine, IL-15 responses were improved generally by 6-to 9-fold by the addition of sIL-15R␣-Fc. Adding sIL-15R␣-Fc also considerably improved the IL-15 response of CD122 hi NK cells (Fig. 1C) but was relatively ineffective on MP (CD44 hi ) CD4 ϩ cells, which express intermediate levels of CD122 (Fig. 1C). Unexpectedly, sIL-15R␣-Fc plus IL-15 led to significant proliferation of typical naïve CD44 lo CD122 lo CD8 ϩ cells, although only with high concentrations o...
SUMMARY Interleukin-2 (IL-2) is a pleiotropic cytokine that regulates immune cell homeostasis, and has been used to treat a range of disorders such as cancer and autoimmune disease. IL-2 signals via interleukin-2 receptor-β (IL-2Rβ):IL-2Rγ heterodimers on cells expressing high (regulatory T cells, Treg) or low (effector cells) amounts of IL-2Rα (CD25). When complexed with IL-2, certain anti-cytokine antibodies preferentially stimulate expansion of Treg (JES6-1) or effector (S4B6) cells, offering a strategy for targeted disease therapy. We found that JES6-1 sterically blocked the IL-2:IL-2Rβ and IL-2:IL-2Rγ interactions, but also allosterically lowered the IL-2:IL-2Rα affinity through a ‘triggered exchange’ mechanism favoring IL-2Rαhi Treg cells, creating a positive feedback loop for IL-2Rαhi cell activation. Conversely, S4B6 sterically blocked the IL-2:IL-2Rα interaction, while also conformationally stabilizing the IL-2:IL-2Rβ interaction, thus stimulating all IL-2 responsive immune cells, particularly IL-2Rβhi effector cells. Our insights provide a molecular blueprint for engineering selectively potentiating therapeutic antibodies.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.